| XLS |
|
|
Merck Serono |
Consumer |
Pharmaceuticals |
Merck Millipore* | ||||||||||||||||||||||
| ||||||||||||||||||||||||||
|
EUR million |
2010 |
2009 |
2010 |
2009 |
2010 |
2009 |
2010 |
2009 | ||||||||||||||||||
|
Sales |
5,409.0 |
4,993.8 |
469.7 |
464.9 |
5,878.7 |
5,458.7 |
1,673.5 |
921.2 | ||||||||||||||||||
|
Royalty, license and commission income |
344.5 |
351.1 |
2.3 |
2.1 |
346.8 |
353.2 |
7.2 |
8.2 | ||||||||||||||||||
|
Total revenues |
5,753.5 |
5,344.9 |
472.0 |
467.0 |
6,225.5 |
5,811.9 |
1,680.7 |
929.4 | ||||||||||||||||||
|
Gross margin |
4,792.8 |
4,485.5 |
316.9 |
319.5 |
5,109.7 |
4,805.0 |
871.0 |
434.5 | ||||||||||||||||||
|
Marketing and selling expenses** |
–1,451.4 |
–1,316.1 |
–235.9 |
–211.9 |
–1,687.3 |
–1,528.0 |
–427.7 |
–231.8 | ||||||||||||||||||
|
Royalty, license and commission expenses** |
–456.2 |
–403.0 |
–1.2 |
–1.5 |
–457.4 |
–404.5 |
–9.9 |
–5.7 | ||||||||||||||||||
|
Administration expenses |
–269.9 |
–263.6 |
–24.7 |
–24.3 |
–294.6 |
–287.9 |
–76.4 |
–43.1 | ||||||||||||||||||
|
Other operating expenses and income |
–169.6 |
–317.4 |
–12.1 |
–9.9 |
–181.7 |
–327.3 |
–140.0 |
–14.0 | ||||||||||||||||||
|
Research and development |
–1,167.1 |
–1,183.6 |
–24.9 |
–19.5 |
–1,192.0 |
–1,203.1 |
–78.0 |
–32.5 | ||||||||||||||||||
|
Operating result |
565.1 |
354.7 |
13.9 |
48.3 |
579.0 |
403.0 |
44.0 |
106.5 | ||||||||||||||||||
|
Exceptional items |
68.6 |
–39.8 |
– |
– |
68.6 |
–39.8 |
– |
10.6 | ||||||||||||||||||
|
Earnings before interest and tax (EBIT) |
633.7 |
314.9 |
13.9 |
48.3 |
647.6 |
363.2 |
44.0 |
117.1 | ||||||||||||||||||
|
Net operating assets |
10,359.7 |
10,015.9 |
310.8 |
336.0 |
10,670.5 |
10,351.9 |
6,486.7 |
781.2 | ||||||||||||||||||
|
Segment liabilities |
–1,268.9 |
–1,078.2 |
–86.4 |
–76.9 |
–1,355.3 |
–1,155.1 |
–374.3 |
–111.5 | ||||||||||||||||||
|
Capital spending on property, plant and equipment |
247.7 |
317.2 |
6.9 |
10.0 |
254.6 |
327.2 |
80.3 |
57.6 | ||||||||||||||||||
|
Investments in intangible assets |
85.1 |
74.8 |
1.3 |
1.4 |
86.4 |
76.2 |
7.2 |
4.9 | ||||||||||||||||||
|
Depreciation and amortization |
–766.5 |
–749.6 |
–11.6 |
–9.5 |
–778.1 |
–759.1 |
–172.7 |
–46.0 | ||||||||||||||||||
|
Impairment losses |
–171.0 |
–99.1 |
–7.1 |
– |
–178.1 |
–99.1 |
–11.0 |
–1.4 | ||||||||||||||||||
|
Net cash flows from operating activities |
1,590.1 |
1,250.7 |
46.6 |
58.0 |
1,636.7 |
1,308.7 |
252.7 |
174.7 | ||||||||||||||||||
|
Net cash flows from investing activities |
–292.0 |
–386.3 |
–1.1 |
–9.1 |
–293.1 |
–395.4 |
–4,924.6 |
–52.1 | ||||||||||||||||||
|
Free cash flow |
1,298.1 |
864.4 |
45.5 |
48.9 |
1,343.6 |
913.3 |
–4,671.9 |
122.6 | ||||||||||||||||||
|
Underlying free cash flow |
1,307.8 |
866.8 |
45.5 |
48.9 |
1,353.3 |
915.7 |
263.4 |
127.7 | ||||||||||||||||||
|
FCR in % |
22.7 |
16.2 |
9.6 |
10.5 |
21.7 |
15.8 |
15.7 |
13.7 | ||||||||||||||||||
|
ROS in % |
9.8 |
6.6 |
2.9 |
10.3 |
9.3 |
6.9 |
2.6 |
11.5 | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
| ||||||||||||||||||
|
|
|
|
|
|
|
|
|
| ||||||||||||||||||
|
|
Performance Materials* |
Chemicals |
Corporate and Other |
Group | ||||||||||||||||||||||
|
EUR million |
2010 |
2009 |
2010 |
2009 |
2010 |
2009 |
2010 |
2009 | ||||||||||||||||||
|
Sales |
1,376.7 |
997.8 |
3,050.2 |
1,919.0 |
– |
– |
8,928.9 |
7,377.7 | ||||||||||||||||||
|
Royalty, license and commission income |
7.7 |
7.9 |
14.9 |
16.1 |
– |
– |
361.7 |
369.3 | ||||||||||||||||||
|
Total revenues |
1,384.4 |
1,005.7 |
3,065.1 |
1,935.1 |
– |
– |
9,290.6 |
7,747.0 | ||||||||||||||||||
|
Gross margin |
924.5 |
478.2 |
1,795.5 |
912.7 |
– |
– |
6,905.2 |
5,717.7 | ||||||||||||||||||
|
Marketing and selling expenses** |
–116.6 |
–99.2 |
–544.3 |
–331.0 |
–2.9 |
–0.3 |
–2,234.5 |
–1,859.3 | ||||||||||||||||||
|
Royalty, license and commission expenses** |
–9.7 |
–2.8 |
–19.6 |
–8.5 |
– |
– |
–477.0 |
–413.0 | ||||||||||||||||||
|
Administration expenses |
–38.5 |
–35.8 |
–114.9 |
–78.9 |
–68.7 |
–58.1 |
–478.2 |
–424.9 | ||||||||||||||||||
|
Other operating expenses and income |
–47.5 |
–8.1 |
–187.5 |
–22.1 |
–21.2 |
–23.3 |
–390.4 |
–372.7 | ||||||||||||||||||
|
Research and development |
–127.1 |
–109.0 |
–205.1 |
–141.5 |
– |
– |
–1,397.1 |
–1,344.6 | ||||||||||||||||||
|
Operating result |
580.0 |
217.8 |
624.0 |
324.3 |
–89.5 |
–78.4 |
1,113.5 |
648.9 | ||||||||||||||||||
|
Exceptional items |
–1.0 |
1.2 |
–1.0 |
11.8 |
–68.4 |
– |
–0.8 |
–28.0 | ||||||||||||||||||
|
Earnings before interest and tax (EBIT) |
579.0 |
219.0 |
623.0 |
336.1 |
–157.9 |
–78.4 |
1,112.7 |
620.9 | ||||||||||||||||||
|
Net operating assets |
1,238.6 |
1,176.2 |
7,725.3 |
1,957.4 |
74.7 |
37.4 |
18,470.5 |
12,346.7 | ||||||||||||||||||
|
Segment liabilities |
–153.9 |
–118.7 |
–528.2 |
–230.2 |
–14.9 |
–15.7 |
–1,898.4 |
–1,401.0 | ||||||||||||||||||
|
Capital spending on property, plant and equipment |
59.1 |
82.1 |
139.4 |
139.7 |
2.2 |
0.4 |
396.2 |
467.3 | ||||||||||||||||||
|
Investments in intangible assets |
3.6 |
7.5 |
10.8 |
12.4 |
7.0 |
8.0 |
104.2 |
96.6 | ||||||||||||||||||
|
Depreciation and amortization |
–98.2 |
–87.6 |
–270.9 |
–133.6 |
–3.2 |
–1.9 |
–1,052.2 |
–894.6 | ||||||||||||||||||
|
Impairment losses |
–16.4 |
–8.1 |
–27.4 |
–9.5 |
–0.2 |
–0.8 |
–205.7 |
–109.4 | ||||||||||||||||||
|
Net cash flows from operating activities |
610.4 |
392.9 |
863.1 |
567.6 |
–717.2 |
–505.0 |
1,782.6 |
1,371.3 | ||||||||||||||||||
|
Net cash flows from investing activities |
–68.2 |
–105.0 |
–4,992.8 |
–157.1 |
1,403.5 |
–1,608.2 |
–3,882.4 |
–2,160.7 | ||||||||||||||||||
|
Free cash flow |
542.2 |
287.9 |
–4,129.7 |
410.5 |
–736.4 |
–511.4 |
–3,522.5 |
812.4 | ||||||||||||||||||
|
Underlying free cash flow |
548.8 |
304.0 |
812.2 |
431.7 |
–495.7 |
–495.8 |
1,669.8 |
851.6 | ||||||||||||||||||
|
FCR in % |
39.6 |
30.2 |
26.5 |
22.3 |
– |
– |
18.0 |
11.0 | ||||||||||||||||||
|
ROS in % |
41.9 |
21.7 |
20.4 |
16.8 |
– |
– |
12.0 |
8.4 | ||||||||||||||||||